1
|
Fukumitsu S, Kinoshita T, Villareal MO, Aida K, Hino A, Isoda H. Maslinic acid improves quality of life by alleviating joint knee pain in the elderly: results from a community-based pilot study. J Clin Biochem Nutr 2017; 61:67-73. [PMID: 28751812 PMCID: PMC5525013 DOI: 10.3164/jcbn.16-119] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2016] [Accepted: 01/25/2017] [Indexed: 12/27/2022] Open
Abstract
Chronic knee joint pain is common in the elderly and associated with poor quality of life. This study, an open-label clinical trial, aimed to examine how the intake on a daily basis of maslinic acid-containing product (30 mg maslinic acid) on 29 elderly residents (mean 70.7 ± 10.1 years) of Nakajima Island, Ehime, Japan. Study participants consumed 10 g jelly containing maslinic acid daily for 16 weeks and at 0 (baseline), 4, 8, 12 and 16 weeks, assessed for health-related quality of life (Short Form-8) and knee pain score (Japanese Knee Osteoarthritis Measure). After 16 weeks, the physical quality of life, more specifically, the level of Bodily Pain and Physical Component Summary, but not mental quality of life, was significantly improved by maslinic acid intake. Furthermore, maslinic acid intake significantly decreased the Japanese Knee Osteoarthritis Measure at week 8 and tended to decrease Visual Analogue Scale score at weeks 4 and 16. These results suggest that consumption of maslinic acid has a protective effect against chronic knee pain in elderly residents in a community where knee pain causes high quality of life burden.
Collapse
Affiliation(s)
- Satoshi Fukumitsu
- Nippon Flour Mills Co., Ltd., Innovation Center, 5-1-3 Midorigaoka, Atsugi, Kanagawa 243-0041, Japan.,Alliance for Research on North Africa (ARENA), University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8572, Japan
| | - Tetsu Kinoshita
- Institute of Community Life Sciences Co., Ltd., Social Epidemiology Institute, Matsuyama, Ehime 791-1102, Japan
| | - Myra O Villareal
- Alliance for Research on North Africa (ARENA), University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8572, Japan.,Faculty of Life and Environmental Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8572, Japan
| | - Kazuhiko Aida
- Nippon Flour Mills Co., Ltd., Innovation Center, 5-1-3 Midorigaoka, Atsugi, Kanagawa 243-0041, Japan
| | - Akihiro Hino
- Nippon Flour Mills Co., Ltd., Innovation Center, 5-1-3 Midorigaoka, Atsugi, Kanagawa 243-0041, Japan
| | - Hiroko Isoda
- Alliance for Research on North Africa (ARENA), University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8572, Japan.,Faculty of Life and Environmental Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8572, Japan
| |
Collapse
|
2
|
Fukumitsu S, Villareal MO, Aida K, Hino A, Hori N, Isoda H, Naito Y. Maslinic acid in olive fruit alleviates mild knee joint pain and improves quality of life by promoting weight loss in the elderly. J Clin Biochem Nutr 2016; 59:220-225. [PMID: 27895390 PMCID: PMC5110940 DOI: 10.3164/jcbn.16-40] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2016] [Accepted: 06/06/2016] [Indexed: 12/18/2022] Open
Abstract
Consumption of olives (Olea europaea L.) is associated with a low incidence of inflammation-related diseases. Olive fruit is rich in bioactive pentacyclic triterpenoids, mainly maslinic acid. This study, a randomized, double-blind, and placebo-controlled trial, examined the effects of an orally administered maslinic acid supplement, olive fruit extract, on 20 middle-aged and elderly volunteers with mild knee joint pain. Each subject (58 ± 7 years) received either olive fruit extract, containing 50 mg maslinic acid (n = 12), or placebo (n = 8) daily for 12 weeks and evaluated for pain and physical functions as primary outcome measures. Secondary outcome measures included body composition and inflammatory biomarkers in serum. Although both groups exhibited improved pain visual analogue scale score and quality of life after supplementation, symptoms were better in the maslinic acid group than in the placebo group. After 12 weeks, maslinic acid group exhibited significant decrease in body weight and body mass index suggesting that maslinic acid affected the weight of volunteers with mild knee joint pain. Therefore, olive products containing maslinic acid may be useful as a new preventive and therapeutic food ingredient for arthritic diseases. Since this clinical study is a preliminary study, it was not registered in a publicly accessible database.
Collapse
Affiliation(s)
- Satoshi Fukumitsu
- Nippon Flour Mills Co., Ltd., Central Laboratory, 5-1-3 Atsugi, Kanagawa 243-0041, Japan
| | - Myra O Villareal
- Faculty of Life and Environmental Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan; Alliance for Research on North Africa (ARENA), University of Tsukuba, Tsukuba, Ibaraki, Japan
| | - Kazuhiko Aida
- Nippon Flour Mills Co., Ltd., Central Laboratory, 5-1-3 Atsugi, Kanagawa 243-0041, Japan
| | - Akihiro Hino
- Nippon Flour Mills Co., Ltd., Central Laboratory, 5-1-3 Atsugi, Kanagawa 243-0041, Japan
| | | | - Hiroko Isoda
- Faculty of Life and Environmental Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan; Alliance for Research on North Africa (ARENA), University of Tsukuba, Tsukuba, Ibaraki, Japan
| | - Yuji Naito
- Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kamigyo-ku, Kyoto, Japan
| |
Collapse
|
3
|
Abalos Medina GM, Ruiz Villaverde G, Sánchez Cano D, Ruiz Villaverde R, Ramírez Rodrigo J, Raya Álvarez E, Villaverde Gutiérrez C. [The impact of therapy with TNF-blockers on health-related quality of life in rheumatoid arthritis patients. A pilot study]. ACTA ACUST UNITED AC 2011; 7:167-71. [PMID: 21794808 DOI: 10.1016/j.reuma.2010.06.004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2010] [Revised: 06/25/2010] [Accepted: 06/28/2010] [Indexed: 01/21/2023]
Abstract
INTRODUCTION The aim of this pilot study was to evaluate the initial response to 16 weeks of treatment with infliximab and etanercept of disease activity and quality of life in a cohort of 37 patients with established rheumatoid arthritis. PATIENTS AND METHOD Patients were selected from the Unit of Rheumatology in Hospital Clínico San Cecilio from Granada, refractory to conventional treatment with disease modifying antirheumatic drugs. To assess the disease activity, Disease activity score (DAS28) was used and the measurement of quality of life was evaluated with the Spanish version of the SF-36 Health Survey (SF-36) and the RA-specific questionnaire QoL Scale (Quality of Life in Rheumatoid Arthritis). RESULTS Preliminary results show a significant decrease in inflammatory activity of the disease and consequently in HRQL scores. The comparison with the general reference population shows a deviation well below average, especially in the "physical function" dimension with a rising response pattern in all dimensions. The correlation between specific scores (QoL-RA scale) and generic ones (SF-36) for HQ-treatment also showed significance, especially with the physical aggregate. DISCUSSION An important limitation of the present study is the number of patients and the duration of the treatment; despite this, improvements in functional parameters and quality of life are evident and remain roughly stable since the first weeks of treatment. This allow us to continue the study and increase the number of patients. CONCLUSIONS The preliminary results obtained with TNF-blockers after 16 weeks of treatment in RA objectively show the effectiveness of these drugs and also the perception by the patients of the effect on their quality of life.
Collapse
|
4
|
Komiya A, Suzuki H, Awa Y, Egoshi KI, Onishi T, Nakatsu H, Ohki T, Mikami K, Sato N, Araki K, Ota S, Naya Y, Ichikawa T. Clinical effect of naftopidil on the quality of life of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a prospective study. Int J Urol 2010; 17:555-62. [PMID: 20370847 DOI: 10.1111/j.1442-2042.2010.02518.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
OBJECTIVES To investigate the benefit of alpha1-adrenoceptor antagonist naftopidil on the quality of life (QOL) of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH/LUTS). METHODS A total of 99 men with BPH/LUTS were prospectively recruited. The Short Form-8 (SF-8) was used for generic QOL assessment and each parameter was compared with the norm in these patients. Longitudinal changes were evaluated using the SF-8 and the International Prostatic Symptoms Score (I-PSS) at baseline, 4 and 8 weeks after naftopidil administration. The relationship between SF-8 and I-PSS was analyzed. RESULTS Five of eight components in the SF-8 were significantly lower than the Japanese national norm at baseline. SF-8 score was improved by naftopidil at 4 and 8 weeks in general health (GH) and physical component summary (PCS) in the patients in their 70s. Mental health (MH) and mental component summary (MCS) were improved at 8 weeks in patients in their 60s. When analyzing the whole cohort, SF-8 GH, role emotional (RE) and MH had improved at 8 weeks, which was similar to the norm, and bodily pain (BP) results were better. Compared with the baseline, total I-PSS, storage/voiding symptoms and QOL index scores improved significantly under naftopidil. Each component of I-PSS (except for hesitancy) correlated with SF-8 sub-scales (except for BP) to some extent. CONCLUSIONS BPH/LUTS impairs generic QOL, which is improved by naftopidil treatment. SF-8 can be a useful instrument to assess the efficacy of BPH/LUTS treatment because its simplicity to complete and analyze, and its meaningful relationship to I-PSS.
Collapse
Affiliation(s)
- Akira Komiya
- Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|